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Abstract
Background: Activated platelets exert a pro-inflammatory action that can be largely ascribed to their ability to interact with
leukocytes and modulate their activity. We hypothesized that platelet activation and consequent formation of monocyte-
platelet aggregates (MPA) induces a pro-inflammatory phenotype in circulating monocytes.
Methodology/Principal Findings: CD62P
+ platelets and MPA were measured, and monocytes characterized, by whole
blood flow cytometry in healthy subjects, before and two days after receiving influenza immunization. Three monocytic
subsets were identified: CD14
+CD16
2, CD14
highCD16
+and CD14
lowCD16
+. The increase in high sensitivity C-reactive protein
post-immunization was accompanied by increased platelet activation and MPA formation (25.02612.57 vs 41.48616.81;
p=0.01), along with enhancement of circulating CD14
highCD16
+ cells (4.763.6 vs 10.464.8; p=0.003), their percentage
being linearly related to levels of CD62P
+-platelets (r
2=0.4347; p=0.0008). In separate in vitro experiments, co-incubation of
CD14
+CD16
2 cells, isolated from healthy donor subjects, with autologous platelets gave rise to up-regulation of CD16 on
monocytes as compared with those maintained in medium alone (% change in CD14
+CD16
+ cells following 48 h co-
incubation of monocytes with platelets was +106651% vs monocytes in medium alone; p,0.001). This effect correlated
directly with degree of MPA formation (r
2=0.7731; p,0.0001) and was associated with increased monocyte adhesion to
endothelial cells. P-selectin glycoprotein ligand-1 (PSGL-1) blocking antibody, which abrogates MPA formation, abolished
these effects, as did the cyclooxygenase (COX)-2 selective inhibitor NS-398, aspirin and the EP1/EP2-selective antagonist
AH6809.
Conclusions/Significance: These data suggest that MPA formation, as occurs in the blood under pro-inflammatory
conditions, expands the pool of circulating CD14
highCD16
+ monocytes in a COX-2 dependent manner, and these monocytes
exhibit increased adhesion to endothelium. Our findings delineate a novel mechanism underlying the pro-inflammatory
effect of platelet activation.
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Introduction
Monocyte-platelet aggregates (MPA) are heterotypic complexes
detectable in the peripheral blood which form in response to
platelet activation [1]. Accordingly, circulating MPA level
increases in patients with acute thrombotic events, such as
myocardial infarction [1,2] or stroke [3,4], as well as in subjects
with underlying atherothrombotic risk factors including hyperten-
sion [5] and diabetes [6]. Circulating MPA are also increased in
patients with a variety of autoimmune disorders [7]. The level of
MPA reflects the degree of platelet hyperactivity thus providing a
robust index of blood thrombogenicity [2]. However, cross-talk
between platelets and monocytes is now regarded as a crucial
pathophysiological mechanism linking thrombosis and inflamma-
tion and is believed to mediate, at least in part, the pro-
inflammatory action of activated platelets. Indeed, in vitro studies
have shown that contact with platelets enhances cytokine and
prostanoid production by monocytes [8–10], as well as their
adhesiveness to the vascular endothelium [11]. However, the
importance of monocyte-platelet interaction in human inflamma-
tory pathophysiology, as well as the precise mechanisms by which
such interaction modulates monocytic function, remain unclear.
Circulating monocytes comprise different sub-populations with
distinct infiltrative and migratory properties, that can be
distinguished on the basis of differential expression of the surface
markers CD14 and CD16 [12,13]. We hypothesized that a mild
systemic inflammatory stimulus will increase circulating MPA,
thus inducing a pro-inflammatory change in monocyte phenotype.
The aims of this study were therefore firstly to investigate in vivo
the effect of a mild acute inflammatory stimulus, namely influenza
immunization [14], on circulating MPA level and monocyte
phenotype; and secondly to determine in vitro the underlying
mechanism by which monocyte-platelet interaction modulates
monocyte phenotype and function.
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Influenza immunization causes an increase in circulating
MPA and a shift in circulating monocytes towards CD16
positivity
Administration of the influenza vaccine induced an increase
in hs-CRP, as expected (0.5760.26 mg/L at baseline vs
2.9461.44 mg/L two days post-immunization, p=0.002). In line
with this, we found an increase in degree of platelet activation, as
reflected by CD62P
+ platelet positivity and level of MPA
(Figure 1A). We also observed a change in distribution pattern
of monocyte subsets, with an expansion of the pool of
CD14
+CD16
+ monocytes (Figure 1B). Within this double positive
pool, the subset of CD14
highCD16
+ monocytes showed the
greatest increase in percentage (from 4.763.61% to
10.4464.79%, p=0.003), whilst the CD14
lowCD16
+ subset did
not change significantly (Figure 1B).
In examining the relationship between the percentage of
CD14
highCD16
+ monocytes and other variables examined (hs-
CRP, CD62P
+platelet and MPA levels), a linear correlation was
found between the CD14
highCD16
+ subpopulation and both hs-
CRP and percentage of CD62P
+ platelets. However, levels of
CD14
highCD16
+correlated more closely to percentage of
CD62P-expressing platelets than with hs-CRP concentration
(Figure 1C).
Detailed characterization of circulating monocytic
subsets and MPA
As shown above, on the basis of CD14 and CD16 expression,
circulating monocytes were distinguished into CD14
+CD16
2,
which constituted the majority, with smaller contributions
from CD14
+CD16
+ cells, comprising CD14
highCD16
+ and
CD14
lowCD16
+ subtypes (Figure 2A). All of these monocytic
subsets expressed the adhesion molecules CD11b and CD11c on
their surface. However, the level of expression of CD11b was
higher on CD14
+CD16
2 cells than on CD14
lowCD16
+ mono-
cytes, whereas these latter cells expressed an increased level of
CD11c compared to the CD14
+CD16
2 subpopulation; the
CD14
highCD16
+ cells demonstrated an intermediate phenotype,
expressing both CD11b and CD11c at high level (Figure 2B).
CD14
highCD16
+ cells also represented the monocytic subtype with
the highest expression level for both TLR-2 and TLR-4.
Specifically, all the different subsets of monocytes were positive
for TLR-2, but the MFI value was higher in CD14
highCD16
+ cells
than in the other monocyte subtypes. TLR-4 was found to be
expressed by 76.35612.3% of CD14
+CD16
2 monocytes,
91.765.8% of CD14
highCD16
+ (p=0.02 vs CD14
+CD16
2) and
82.0367.26% of CD14
lowCD16
+ cells (p.0.05 vs CD14
+CD16
2).
Moreover, CD14
highCD16
+ cells exhibited higher MFI for TLR-4
compared to the other monocytic subtypes (Figure 2C).
Circulating MPA, as defined by double positivity for CD14 and
CD42b, accounted for 15.266.7% of the monocytic population.
No significant difference was observed in the ability of the different
monocyte subpopulations to interact with platelets (Figure 2D)
although, as expected, the number of CD14
+CD62P
+ events was
less than the number of CD14
+CD42b
+ events.
Monocyte-platelet interaction leads to a phenotypic
change of CD14
+CD16
2 monocytes towards
CD14
+CD16
+
An initial experiment was performed to study the kinetics of
CD16 expression and MPA formation, when monocytes in culture
were co-incubated with either autologous platelets or medium
alone, for up to 48 h. Monocytes in medium alone showed a
progressive time-dependent increase of CD16 cell surface
expression. Co-incubation with platelets up-regulated CD16
expression to a greater degree from 18 h onwards (Figure 3A).
MPA formation increased in a time-dependent manner, even
when monocytes were incubated with medium alone; this reflects
an unavoidable degree of platelet contamination of the monocyte
sample, with resultant MPA formation. Nevertheless, the addition
of exogenous platelets to the culture medium substantially
augmented MPA formation, at all time points examined from
18 h onwards (Figure 3B).
On the basis of these results, in subsequent experiments the
effect of platelets (or corresponding medium) on CD16 expression
in isolated monocytes was investigated at 24 h and 48 h of co-
culture, whilst the effect on MPA formation was measured at 48 h.
These experiments confirmed that co-incubation with platelets for
48 h caused significant up-regulation of CD16 on monocytes as
compared with medium alone (Figure 3C), and an increase in
MPA formation (Figure 3D). Regression analysis showed a direct
relationship between level of MPA formation and percentage of
monocytes expressing CD16 at 48 h (Figure 3E).
Although CD16 induction was also seen in monocytes
incubated with PCM for 48 h, the percentage of CD16
+ cells
was considerably lower than that achieved by incubation with
platelets (Figure 4A). As expected, MPA levels following monocyte
culture in PCM was unchanged compared to monocytes in
medium alone (Figure 4B), as were levels of soluble P-selectin in
the medium (Figure 4C). However, soluble P-selectin levels were
much greater following monocyte co-culture with platelets
(Figure 4C).
In order to ascertain whether P-selectin binding to monocytic
PSGL-1 is in itself sufficient to induce the phenotypic changes
observed in monocytes, we examined the effect of co-incubation
with anti-human PSGL-1 blocking antibody or isotype control.
Blockade of PSGL-1 abrogated MPA formation from monocytes
in the presence of platelets, and also markedly reduced the degree
of induction of CD16 expression (Figure 3F). Similarly, anti-
PSGL-1 blocking antibody abolished the PCM-induced up-
regulation of CD16 on monocytes (Figure 4A). However, soluble
P-selectin alone, when added to the culture medium of
CD14
+CD16
2 monocytes, exerted no demonstrable effect on
CD16 expression in monocytes, even at concentrations as high as
those found in the supernatants of monocyte-platelet co-cultures
(Figure 4D).
CD14
+CD16
+ monocytes exhibit increased adhesiveness
to activated endothelium
In monocytes co-incubated with platelets as well as in those
maintained in medium alone, cells adhering to TNF-a-pre-
activated HUVEC were almost exclusively CD14
+CD16
+; only
occasional monocytes expressing CD14 but not CD16 were
Figure 1. Effect of influenza immunisation on platelet activation and monocyte phenotype. Percentage of CD62P
+platelets and MPA (A),
and monocyte characterization (B), measured at baseline (PRE) and 2 days after influenza immunization (POST). Figures show representative dot plots
obtained from flow cytometry, as well as accumulated data from n=12 experiments. Monocytic subsets are designated R1 (CD14
+CD16
2), R2
(CD14
highCD16
+) and R3 (CD14
lowCD16
+). (C), Regression analyses for CD14
highCD16
+ monocytes (R2) vs CD62P
+platelets and vs hs-CRP.
doi:10.1371/journal.pone.0025595.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25595Figure 2. Circulating MPA and monocyte characterization. (A) Percentage of the different circulating monocyte subpopulations, with a
representative whole blood flow cytometry dot plot showing CD14 and CD16 expression, as well as accumulated data from n=10 experiments
presented graphically. (B) Representative flow cytometry dot plots for CD14 and CD11b (left) or CD11c (right) in the different monocyte subsets.
Graph displays MFI values for CD11b (filled bars) and CD11c (open bars) in each subset (n=10). (C), Representative flow cytometry dot plots for CD14
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+CD16
+ cells showed a higher
expression of both CD11b and CD11c compared with the
CD14
+CD16
2 subtype (Figure 4C). Pre-treatment of monocytes
with platelets increased the number of CD14
+CD16
+ monocytes
attaching to HUVEC (Figure 5A and 5B).
COX-2 induction and consequent PGE2 generation
underlies the phenotypic changes observed in
monocytes in response to interaction with platelets
As previously reported [10], co-incubation with platelets for
18 h induced COX-2 expression in monocytes (Figure 6A). Since
this effect temporally preceded the phenotypic and functional
changes described above in response to monocyte-platelet co-
culture (Figure 3), we wished to determine whether COX-2
induction was responsible for inducing these changes, by
examining the effect of COX-2 inhibition on monocyte phenotype
and function. Platelet-dependent up-regulation of CD16 on
monocytes was markedly reduced by the COX-2 selective
inhibitor NS-398, while no effect was observed in response to
the COX-1 selective inhibitor SC-560; aspirin also reduced
platelet-dependent up-regulation of monocytic CD16, to a degree
comparable to NS-398 (Figure 6B). MPA formation was not
affected by SC-560, NS-398 or aspirin (Figure 6C). Treatment
with NS-398 also led to a marked reduction in the number of
monocytes adhering to TNF-a-pre-activated HUVEC (Figure 5B)
As before, we found that CD14
+CD16
+ cells exhibited an
advantage in binding to HUVEC over the CD14
+CD16
2 subset.
In order to clarify whether the effects on CD16 expression
obtained with NS-398 and aspirin, but not with SC-560, were
attributable to differential responsiveness of monocytes to the
COX-1- and COX-2-derived prostanoids thromboxane A2 and
PGE2 respectively [15], the mRNA expression of TP and EP
receptors was studied (Figure 7A). TP expression was found in
CD14
+CD16
2 monocytes immediately after isolation, whilst after
48 h incubation, either in medium alone or with platelets, it
became undetectable. Freshly isolated CD14
+CD16
2 cells ex-
pressed PGE2 receptors, mainly EP2 and EP4 isoforms, with only
small amounts of EP1 and no EP3 mRNA detectable. After 48 h
incubation in medium alone, mRNA for EP2 and EP4 were still
detectable, albeit at lower levels than in freshly isolated cells;
moreover, EP1 mRNA also became undetectable. Notably, when
monocytes were co-incubated with platelets for 48 h, the decrease
in mRNA for EP1, EP2 and EP4 was less than that observed in
monocytes cultured in medium.
We next examined the effect of different PGE2 receptor
antagonists on platelet-dependent CD16 up-regulation in mono-
cytes (Figure 7B) as well as on MPA formation (Figure 7C). The
EP1/EP2-selective antagonist AH6809 markedly reduced mono-
cytic CD16 up-regulation. Although the EP4-selective antagonist
AH23848 appeared also to decrease CD16 up-regulation, this did
not reach significance, and there was no additive effect of
AH23848 and AH6809, suggesting that the EP1 and/or EP2
are predominantly involved in modulating monocytic CD16 up-
regulation in response to platelet interaction. Moreover, the effect
of AH6809 on the CD16 increase was similar to that seen in
response to NS-398, aspirin or anti-PSGL-1 blocking antibody
(Figure 6B). The two EP antagonists also reduced formation of
MPA in vitro, with this effect being significant when they were
used in combination rather than singly; and their combined effect
was comparable to that in response to anti-PSGL-1 blocking
antibody (Figure 7C).
Discussion
The present data demonstrate that MPA formation gives rise to
a phenotypic change of circulating monocytes toward CD16
+ cells,
which display increased endothelial adhesiveness. We have shown
that this change is mediated by platelet-dependent COX-2 up-
regulation and consequent PGE2 synthesis in monocytes, and that
this process can be prevented by selective blockade of either COX-
2 enzymatic activity or EP receptors.
CD14
+CD16
+ cells identify a subgroup of circulating monocytes
with higher pro-inflammatory activity than the ‘‘classical’’
CD14
+CD16
2 subpopulation [13]. To date, no direct evidence
exists in the literature that double positive cells originate from
‘‘classical’’ monocytes. This study is the first to show that the
presence of activated platelets, with consequent MPA formation,
induces CD16 up-regulation on CD14
+CD16
2 monocytes.
Although other groups have reported that platelets can alter
monocytic CD16 expression [16], this has been interpreted as an
effect on terminal monocytic maturation toward macrophages;
however, our in vitro results together with our in vivo data point to a
change in circulating monocyte phenotype rather than a terminal
differentiation event. Importantly, due to the isolation techniques
used in previous studies (elutriation of peripheral blood mononu-
clear cells), circulating double positive monocytes were included in
the cells under investigation; and since CD16 antigen was
measured in the cell supernatant, the prior presence of
CD14
+CD16
+ monocytes is likely to have affected the results
obtained in such studies. Our in vitro experiments were performed
specifically with isolated CD14
+CD16
2 monocytes, using flow
cytometry which allowed the direct detection of CD16 on their
cellular surface, enabling us to measure the percentage of cells
developing positivity for the CD16 marker over time. Moreover,
we have quantified the degree of interaction between monocytes
and platelets by measuring monocyte-platelet complexes formed in
vitro. Interaction with platelets up-regulated CD16 antigen on
isolated monocytes, with this effect being directly related to the
level of MPA. Although simple co-incubation of CD14
+CD16
2
monocytes with human recombinant P-selectin did not induce
CD16 expression, anti-PSGL-1 blocking antibody, which we have
found to abrogate MPA formation,
5 abolished platelet-induced
over-expression of CD16 on monocytes, demonstrating that
physical contact of monocytes with platelets is critical in this
process, most likely by P-selectin/PSGL-1 binding sustaining
multiple receptor-ligand interactions between these cells which
trigger the final phenotypic changes.
On the other hand, our experiments suggest that soluble
mediators released during the process of platelet activation also
exert an important modulatory effect on monocyte phenotype,
since CD16 up-regulation was induced by PCM, albeit to a much
lower extent than platelets. Nevertheless, PSGL-1 blockade
completely abolished both platelet-dependent and PCM-depen-
dent CD16 up-regulation, suggesting that engagement of mono-
cytic PSGL-1 by either soluble or platelet-associated P-selectin is
and TLR-2 (left) or TLR-4 (right) in the different monocyte subsets. Graph displays MFI values for TLR-2 (filled bars) and TLR-4 (open bars) in each
subset (n=10). (D) Representative flow cytometry dot plots for CD14 and CD42b (left panel) or CD62P (right panel). Graph shows data accumulated
from n=10 experiments illustrating the % MPA formed by the different monocytic subsets, as determined from CD14
+CD42b
+ (filled bars) or
CD14
+CD62P
+ events (open bars). In black, red and blue are CD14
+CD16
2 (R1), CD14
highCD16
+ (R2) and CD14
lowCD16
+ (R3). *,**, *** p,0.05, ,0.01
and ,0.001 respectively vs R3.
{, { p,0.05 and ,0.01 respectively vs R1.
doi:10.1371/journal.pone.0025595.g002
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change in monocyte phenotype.
This study provides important information as regards the
mechanism by which platelet-monocyte interaction modulates
monocyte phenotype and function, involving platelet-dependent
COX-2 up-regulation in monocytes. The selective COX-2
inhibitor NS-398 not only prevented the increased CD16
expression on monocytes co-incubated with platelets, but also
reduced monocytic interaction with activated endothelium. In
parallel with these findings, selective blockade of EP1/EP2
mirrored the effects observed with COX-2 inhibition. Of note,
we found that aspirin counteracted platelet-dependent up-
regulation of CD16 on monocytes co-incubated with platelets to
a similar extent as NS-398. Others have demonstrated that aspirin,
used at concentrations similar to that used in our experiments,
modulates PGE2 synthesis in monocytes and gives rise to similar
effects as those caused by COX-2 specific inhibition [17];
additionally, the COX-1 selective inhibitor SC-560 has been
found to be less effective than the COX-2 selective inhibitor NS-
398 in reducing PGE2 production by bone marrow-derived
dendritic cells [18]. It is likely that, in our in vitro experiments,
aspirin blocked monocytic PGE2 production by COX-2 inhibition,
since the same effect on CD16 up-regulation was seen with NS-
398 but not with SC-560.
The phenotypic changes induced by MPA formation were
found to modulate adhesiveness of monocytes to endothelium.
These experiments were performed under static conditions, and in
future studies it will be instructive to also assess monocyte adhesion
to endothelium under conditions of flow. Nevertheless, our data
suggest that CD14
+CD16
+ monocytes have greater potential to
adhere to activated endothelium than CD14
+CD16
2 monocytes.
In our adhesion assay, monocyte interaction with endothelial cells
occurred through a mechanism independent of bridging via
activated platelets. Indeed, the presence of the COX-2 inhibitor in
our co-culture experiments reduced monocytic adhesion to
endothelial cells, despite the fact that the same level of MPA was
present in the cell suspension added. The reduction in
CD14
+CD16
+ monocytes in response to COX-2 inhibition
resulted in reduced binding of isolated monocytes to activated
endothelium. The different adhesive properties of the various
monocytic subsets may be attributed to differential expression of
adhesion molecules on their cellular surface. CD11b and CD11c
have been recognized as crucial mediators of monocyte-endothe-
lium interaction [19,20]. We observed that CD16
+ cells, both
those developed in vitro and those found in the peripheral blood of
healthy subjects, display higher levels of these integrins on their
surface compared to monocytes positive for CD14 only.
We also observed that other molecules involved in the activation
of monocytes and their pro-inflammatory activity [21,22], namely
TLR-2 and TLR-4, are expressed on CD14
+CD16
+ monocytes to
a higher degree than on other subsets. CD14
+CD16
+ cells did not
differ from the other monocyte subpopulations in ability to bind
activated platelets and form MPA, at least in healthy subjects;
accordingly, in our influenza immunization study, similar levels of
MPA formed by each subset of monocytes were observed both at
baseline and post-immunization. Therefore, the increased levels of
MPA seen in the context of an acute inflammatory state, such as
that induced by influenza immunization, are likely attributable to
increased platelet activation. In our experimental model of
inflammation, we found that the increase in hs-CRP, activation
of platelets and consequent MPA formation are accompanied by
an increase in the percentage of CD16
+ monocytes in the
circulation, mainly driven by expansion of the CD14
highCD16
+
subpopulation. It cannot be excluded that the vaccine per se drives
the phenotypic changes observed on circulating monocytes.
However, the level of CD14
highCD16
+ cells was found to be
strongly and directly related to the percentage of CD62P
+
platelets, suggesting that the degree of platelet activation influences
the phenotype of monocytes in the peripheral blood by shifting
them towards positivity for CD16. Although these results suggest
that accumulation of CD14
highCD16
+ cells in vivo is a platelet-
driven phenomenon, this would require confirmation in future in
vivo studies, for example using animal models where platelets are
depleted. In future studies, it would also be useful to ascertain if the
effects of COX inhibition which we have here reported in vitro can
be replicated in vivo in human subjects.
Our data provide evidence that a host of modifications occur in
the phenotype of circulating monocytes in response to a pro-
inflammatory stimulus, rendering them more pro-inflammatory
and with increased endothelial adhesiveness, and that these are
strongly related to – and are likely to be driven by – the extent of
platelet activation. Our findings shed new light on the relevance of
platelet-monocyte interactions in the pathophysiology of inflam-
mation, and may provide a novel therapeutic target in patients
with inflammatory disorders.
Materials and Methods
Ethics statement
The study was approved by St Mary’s Hospital Research Ethics
Committee, London, UK. All participants gave written informed
consent.
Effect of influenza immunization on circulating MPA and
monocyte phenotype
Twelve healthy subjects (9 male, 3 female; age 25–30 years)
were recruited sequentially, from employees of Guy’s and St
Thomas’ NHS Foundation Trust who were attending the Trust’s
Occupational Health service to receive influenza immunization.
Subjects were studied immediately before, and 2 days following,
influenza vaccine administration. At the first visit, blood (32 ml)
was taken for full blood count and biochemistry screening, as well
as for high sensitivity C-reactive protein (hs-CRP) assay,
measurement of CD62P+ platelets (reflecting degree of platelet
activation), determination of MPA level and characterization of
monocytes. At the second visit, blood (4 ml) was once again taken,
for repeat determination of hs-CRP, CD62P+ platelets and MPA,
as well as monocyte characterization.
Percentage of CD62P+ platelets was analyzed by flow cytometry
(FACSCalibur, Becton Dickinson (BD), Oxford, UK) on whole
blood immunostained with fluorescein isothiocyanate (FITC)-
conjugated anti-human CD42b and allophycocyanin (APC)-
Figure 3. Effect of platelets on monocyte phenotype. Percentage of CD14
+CD16
+ monocytes (A) and MPA (B), following incubation of
monocytes with platelets (M+P, solid line) or medium alone (M, dotted line) for different times (n=1). Dot plots show flow cytometry analysis after
48 h culture. Accumulated results from n=10 experiments showing percentage of CD14
+CD16
+ monocytes (C) and MPA (D) after co-incubation of
monocytes with platelets (M+P) or medium alone (M). (E), Regression analysis of MPA level vs percentage of CD14
+CD16
+ cells at 48 h. (F), Percentage
of CD14
+CD16
+ cells (upper panel) and MPA (lower panel) after co-incubation of monocytes with platelets for different times, either in the presence
of isotype antibody (solid line) or anti-PSGL-1 blocking antibody (dotted line) (n=4). **, *** p,0.01 and ,0.001 respectively vs anti-PSGL-1.
doi:10.1371/journal.pone.0025595.g003
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+CD16
+ monocytes (A) and MPA (B),
following 48 h incubation of monocytes in medium alone (M), platelet-free conditioned medium either in the absence (M+PCM) or presence of anti-
PSGL-1 blocking antibody (M+PCM+anti-PSGL-1), or platelets (M+P) (n=3 for each). (C), Soluble P-selectin measured in the supernatant of monocytes
cultured for 48 h under different experimental conditions as shown. (D), Percentage of CD14
+CD16
+ monocytes after 48 h exposure to different
concentrations of soluble P-selectin. *** p,0.001 vs M.
doi:10.1371/journal.pone.0025595.g004
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events in total were acquired within the platelet gate, as identified
on forward and side light scatter plot. MPA determination and
monocyte characterization were performed by whole blood flow
cytometry, as described below.
Monocyte characterization and MPA measurement in
peripheral blood
In all further experiments, a separate cohort of 15 healthy
subjects (10 male, 5 female; age 25–35 years) was studied.
Monocyte characterization and MPA measurement were per-
formed by flow cytometry analysis on whole blood (4 ml) collected
in sodium citrate (0.3% final concentration). Immediately after
venepuncture, 100 ml blood was immunostained with different
combinations of the following antibodies: peridinin chlorophyll
protein complex (PerCP)-conjugated anti-human CD14, FITC-
conjugated anti-human CD16, APC-conjugated anti-human
CD42b or CD62P, phycoerythrin (PE)-conjugated anti-human
CD11b or CD11c (all from BD Bioscience), and APC-conjugated
anti-human Toll-like receptor (TLR)-2 or 4 (eBioscience, UK).
Isotype control antibodies were used as negative control. After red
cell lysis using FACS lysing solution (BD Bioscience), samples were
fixed in 1% paraformaldehyde and kept at 4uC until analyzed
within a maximum of 48 h from sample preparation.
Forward and side light scatter parameters were used to access
the monocyte population, and a total of 20,000 events acquired.
The negative and positive delineators were determined from the
isotype control fluorescence.
Monocyte subsets were identified by double immunostaining for
CD14 and CD16. The percentage of CD14+ cells also expressing
CD42b (all platelets) or CD62P (activated platelets) was also
calculated and taken as representative of MPA. By gating for each
monocyte subtype, percentage of cells positive for CD11b/c or
TLR-2/4 as well as the mean fluorescence intensity (MFI) for
CD11b/c or TLR-2/4 was analyzed. Post-acquisition analysis was
performed using FlowJo software (Tree Star, Ashland, OR).
Monocyte and platelet co-culture
Whole blood (30 ml) collected in EDTA was subjected to
Lymphoprep gradient centrifugation. Mononuclear cells under-
went immunomagnetic negative selection for CD14+CD16-
monocytes (kit from Invitrogen) according to the manufacturer’s
Figure 5. Effect of platelets on monocyte adhesiveness to endothelial cells and expression of adhesion molecules.
(A), Photomicrographs showing CD14-PE (red) and CD16-FITC (green) staining of monocytes adhering to TNF-a-pre-activated HUVEC (stained
with HOECHST, blue), following 48 h culture in medium alone (M) or in the presence of platelets (M+P). (B), Number of monocytes/field following
48 h pre-culture in medium alone (M), in the presence of platelets (M+P) either with or without NS-398 (n=3). ** p,0.01 vs M. (C), Expression of
CD11b (filled bars) and CD11c (open bars) in the same cellular suspension tested in the HUVEC adhesion assay, in monocyte subpopulations classified
according to CD14 and CD16 positivity. *p,0.05 vs CD14
+CD16
2.
doi:10.1371/journal.pone.0025595.g005
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expression (CD14
+, CD16
2, CD3
2, CD4
2, CD8
2, CD20
2)
using flow cytometry, was 78–82% in all experiments. Isolated
cells were resuspended in serum-free RPMI-1640 (10
6cells/ml),
and transferred to polystyrene tubes.
Platelets were pelleted by centrifugation of plasma at (14006g,
4uC, 6 min). The pellet was resuspended, under sterile condition,
in PBS containing 5 mmol/l EDTA, and platelets were centri-
fuged (5006g, room temperature, 5 min) and resuspended
(25610
9 platelets/ml) in serum-free RPMI-1640. Platelet-condi-
tioned medium (PCM) was obtained by stirring isolated platelets in
serum-free RPMI-1640 (1200 rpm, 10 min, 4uC), followed by
removal of platelets by centrifugation (10,0006g, 3 min, room
temperature) and collection of supernatant.
Aliquots of purified autologous platelets or equal volumes of
PCM were added to monocyte suspensions (1 ml final volume,
monocyte:platelet ratio 1:100 in experiments where platelets were
added) and incubated at 37uC, 4% CO2 for 48 h. Although these
experiments were performed in the absence of pharmacological
platelet agonists, the platelet isolation and culture procedure prior
to addition to monocytes induced platelet activation, with P-
selectin expression measured at 8763%. Co-incubation of
monocytes with platelets or PCM was also performed in the
presence of monoclonal anti-human PSGL-1 blocking antibody
(10 mg/ml; Chemicon), and the effect compared to that obtained
with isotype control (mouse anti-human IgG, 10 mg/ml; Chemi-
con).
Viability of monocytes, as assessed by Trypan Blue dye
exclusion, was .95% immediately after their isolation and after
48 h culture, either in the presence or absence of platelets/PCM.
CD16 expression and MPA formation were assessed by flow
cytometry at different time points. The supernatants were also
collected and soluble P-selectin measured according to the
manufacturer’s instructions (R&D System, UK).
In separate experiments, monocytes were treated for 48 h with
increasing concentrations of soluble human recombinant P-
selectin (0–240 ng/ml, R&D System), and monocytes character-
ized as before.
Investigation of the role of COX-2 and prostaglandin E2
in modulating MPA and monocyte phenotype
We investigated cyclooxygenase type 2 (COX-2) induction in
monocytes co-incubated for 18 h with either platelets or medium
alone. Following such incubation, cells were permeabilized with
Triton X-100 0.01%, and immunostained for 20 min at 4uCi n
PBS/0.2% bovine albumin serum containing PE-conjugated
mouse anti-human COX-2 antibody (Calbiochem,UK; 1 mg/
ml). After washing in PBS and fixation in 1% paraformaldeyde,
cells were resuspended in 10 ml PBS, seeded on a microscope slide
and examined under fluorescence microscopy (406magnification,
Zeiss LSM, 510 META).
CD16 expression and MPA formation were analyzed following
monocyte co-incubation with platelets for 48 h, either in the
presence or absence of different COX inhibitors: NS-398 (10 mM,
a COX-2-selective inhibitor) [23], SC-560 (30 nM, a COX-1-
selective inhibitor) [23] and aspirin (0.5 mM, a non-selective COX
inhibitor). The effect of prostaglandin E2 (PGE2) receptor blockade
on CD16 expression and MPA level was also examined using the
EP1/EP2-selective antagonist AH-6809 (10 mM; Cayman) and the
EP4-selective antagonist AH-23848 (10 mM; Cayman) [24], either
alone or in combination. NS-398, aspirin and EP antagonists were
resuspended in DMSO/PBS solution (1:3), whilst SC-560 was
resuspended in ethanol. In all experiments, the effects of each
antagonist were compared to those obtained using the respective
vehicle.
Expression at the mRNA level of the thromboxane receptor
(TP) (a-isoform) and the different PGE2 receptors (EP1, EP2, EP3
and EP4) was studied by semi-quantitative reverse transcriptase
polymerase chain reaction (RT-PCR), in freshly isolated mono-
cytes and those cultured for 48 h either in medium alone or with
platelets. Total RNA was extracted by phenol-chloroform
Figure 6. Platelet-dependent COX-2 up-regulation in mono-
cytes and effect of COX inhibitors on monocytic CD16
expression and MPA formation. (A), Immunofluorescence staining
for COX-2 (red) in monocytes cultured in medium alone (M) or with
platelets (M+P) for 18 h. Photomicrographs are representative of n=3
experiments. Change in CD16 expression (B) and MPA (C) in monocytes
co-cultured with platelets, expressed as % change in CD14
+CD16
+ and
CD14
+CD42b
+ cells respectively, as compared to monocytes cultured in
medium alone, after 48 h. Also shown are the effects of NS-398, SC-560
and aspirin addition to monocyte-platelet co-culture (n=3–4).
*, ** p,0.05 and ,0.01 respectively vs M.
doi:10.1371/journal.pone.0025595.g006
Effect of Platelets on Monocyte Phenotype
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e25595extraction (TRIZOL, Invitrogen) and resuspended in RNase- and
DNase-free water. RNA concentration was analyzed by Nano-
Drop and 500 ng total RNA used for cDNA synthesis. Equal
aliquots of cDNA were then PCR-amplified by Taq Polymerase
(Invitrogen, UK) in a 40 ml reaction containing 16 Buffer,
250 mM dNTPs, 4 mM MgCl2, 1.25 mM of each primer, 2U
Taq. The conditions of amplification were as follows: an initial
5 min at 95uC for denaturation; 36 cycles of 95uC for 1 min, 60uC
for 1 min and 72uC for 1 min 30 s; and a final extension step of
72uC for 10 min. The sense and antisense primers used, and the
expected product sizes, are listed in Table 1.
Monocyte adhesion to endothelial cells
Human umbilical vein endothelial cells (HUVEC) were isolated
from fresh umbilical cords obtained from uncomplicated deliveries
following healthy pregnancies; these were obtained from the
labour ward at St Thomas’ Hospital, with written informed
consent from the mothers. HUVEC were isolated using previously
Figure 7. Role of COX-2 up-regulation and of PGE2 on platelet-dependent monocytic CD16 expression and MPA formation.
(A)mRNAlevelofEPandTPreceptorsinfreshlyisolatedmonocytes(lane1),andafter48 hcultureeitherwithmediumalone(lane2)orplatelets(lane3).
18S ribosomal RNA expression is shown as housekeeping RNA. Experiment is representative of n=3. Effects of AH6809 and AH3848, alone or in
combination (COMB), NS-398, aspirin or anti-PSGL-1 blocking antibody on CD16 expression (B) and MPA (C) in monocytes co-cultured with platelets for
48 h, expressed as % change in CD14
+CD16
+ and CD14
+CD42b
+ as compared to monocytes co-cultured with platelets alone. * p,0.05 vs M+P.
doi:10.1371/journal.pone.0025595.g007
Table 1. Primer sequences used for RT-PCR.
GENE Forward Primer (59-39) Reverse Primer (59-39) Product size (bp)
EP1 TTGTCGGTATCATGGTGGTG ATGTACACCCAAGGGTCCAG 160
EP2 GTCTGCTCCTTGCCTTTCAC CGACAACAGAGGACTGAACG 176
EP3 ATCTCAGTCCAGTGCCCAGT TTTCTGCTTCTCCGTGTGTG 172
EP4 CTGGTGGTGCTGATCTGCT TATCCAGGGGTCTAGGATGG 150
TP AGGTGGAGATGATGGCTCAG CGGCGGAACAGGATATACAC 220
doi:10.1371/journal.pone.0025595.t001
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HUVEC were seeded onto coverslips in 12-well plates. The
following day, HUVEC were stimulated with tumor necrosis
factor-a (TNF-a, 10 ng/ml, Invitrogen) for 3 h at 37uC, and then
washed with PBS. A cell suspension containing monocytes pre-
cultured either in medium alone or with platelets for 48 h was
added to the coverslip cultures. After further 2 h incubation at
37uC, non-attached cells were removed by vigorous pipetting.
Immunostaining using PE-conjugated anti-CD14 and FITC-
conjugated anti-CD16 was then performed at 4uC for 20 min.
After washing in PBS twice, HOECHST solution was added for
nuclear staining and removed after 2 min incubation, following
which cells were fixed in 1% paraformaldeyde. The coverslips
were mounted on slides with mounting medium and analyzed by
fluorescence microscopy. Cells positive for monocytic markers
were counted in ten fields (206magnification).
Statistical analysis
All data are presented as mean 6 SD. Statistical analysis was
performed using GraphPad Prism 4 software. Differences in level
of hs-CRP, CD62P+ platelets, MPA and monocyte phenotype
before and after influenza vaccine were evaluated by paired
Student’s t test, and the associations between these different
parameters were analyzed by least squares and multiple regression
analyses. All other statistical comparisons were by ANOVA, with
or without repeated measures as appropriate. In all cases, P,0.05
(two-tailed) was taken to indicate statistical significance.
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